Spyre Therapeutics, Inc. (SYRE)

Market Cap	958.41M
Revenue (ttm)	n/a
Net Income (ttm)	-159.24M
Shares Out	60.35M
EPS (ttm)	-3.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	71,693
Open	15.76
Previous Close	15.96
Day's Range	15.47 - 15.94
52-Week Range	10.91 - 40.26
Beta	2.69
Analysts	Buy
Price Target	55.00 (+246.35%)
Earnings Date	Aug 6, 2025

About SYRE

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-α4β7) and SPY...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2016
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: SYRE
• Website: https://www.spyre.com

Analyst Summary

According to 6 analysts, the average rating for SYRE stock is "Buy." The 12-month stock price target is $55.0, which is an increase of 246.35% from the latest price.

Price Target

$55.0

(246.35% upside)

Analyst Consensus: Buy